Interní Med. 2005; 7(5): 265-266

Liečba hlbokej venóznej trombózy

prof. MUDr. Ján Murín CSc
I. interná klinika FN a LFUK, Bratislava

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Murín J. Liečba hlbokej venóznej trombózy. Interní Med. 2005;7(5):265-266.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-169. Go to original source... Go to PubMed...
    2. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526. Go to original source... Go to PubMed...
    3. Brandjes DPM, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW, Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-1489. Go to original source... Go to PubMed...
    4. Francis CW, Ginsberg JS, Berkowitz SD, et al. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE Treatment Study. Blood 2003;102:6a. abstract.
    5. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Circulation 1996; 93: 2212-2245. Go to original source... Go to PubMed...
    6. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin:mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (Suppl): 64S-94S. Go to original source... Go to PubMed...
    7. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119 (Suppl): 176S-193S. Go to original source... Go to PubMed...
    8. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deepvein thrombosis. Lance 1969; 2: 230-232. Go to original source... Go to PubMed...
    9. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended antiocagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907. (Erratum, N Engl Med 1999; 341: 298) Go to original source... Go to PubMed...
    10. Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med 2001; 1: 7-26. Go to original source... Go to PubMed...
    11. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153. Go to original source... Go to PubMed...
    12. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681. Go to original source... Go to PubMed...
    13. Linkins L, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral antiicoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900. Go to original source... Go to PubMed...
    14. Moser KM, LeMoine JR, Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981; 94: 439-444. Go to original source... Go to PubMed...
    15. Moser KM, Fedullo PF, LittleJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994; 271: 223-225. (Erratum, JAMA 1994; 271: 1908) Go to original source...
    16. Nordstom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232; 155-160. Go to original source... Go to PubMed...
    17. Pettila V, Leinonen, P, Markkola A, Hiilesmaa V, Kaaja R. Postprtum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182-186. Go to original source... Go to PubMed...
    18. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis, Circulation 2001; 103: 2453-2460. Go to original source... Go to PubMed...
    19. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173. Go to original source... Go to PubMed...
    20. Shulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665. Go to original source... Go to PubMed...
    21. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593. Go to original source... Go to PubMed...
    22. Stamatakis JD, Kakkar VV, Sagar S, Lawrence D, Nairn D, Bentley PG. Femoral vein thrombosis and total hip replacement. Br Med J 1977; 2: 223-225. Go to original source... Go to PubMed...
    23. The MATISSE Investigators. The MATISSE-DVT trial, a randomized, doubleblind study comparing once-daily fondaparinux Arixtra. with low-molecular-weight haparin LMWH. enoxaparin, twice daily, in the initial treatment of symptomatic deep vein thrombosis DVT. In: program and abstracts of the XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, England, July 12-18, 2003. Malden, Mass: Blackwell Publishing, 2003. Abstract computer disk.
    24. van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2000; 4: CD002001. Go to original source...
    25. Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still an indication? Thromb Haemost 2001; 86: 499-508. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.